Inovio Pharmaceuticals Inc INO shares are trading lower by 9.9% at $8.65 after the company reported worse-than-expected second-quarter EPS and sales results.
Inovio Pharmaceuticals reported quarterly losses of 39 cents per share which missed the analyst consensus estimate of a loss of 25 cents per share. Inovio Pharmaceuticals also reported quarterly sales of $272,820 which missed the analyst consensus of $1.21 million.
Dr. J. Joseph Kim, President and CEO of Inovio, noted, "In parallel with our global INNOVATE Phase 3 trial, we continue to prepare INOVIO's next-generation, pan-COVID vaccine candidate, INO-4802, in a Phase 1/2 trial entitled IMPACT (INOVIO INO-4802 Multi-variant Pan-COVID-19 Vaccine Trial), where the goal is to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine or as a boost."
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases.
Inovio has a 52-week high of $19.66 and a 52-week low of $5.81.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.